IRLAB Therapeutics AB's quarterly market cap
declined
from Sep. 2025 (kr248.01 Mil) to Dec. 2025 (kr167.32 Mil) and
declined
from Dec. 2025 (kr167.32 Mil) to Mar. 2026 (kr127.57 Mil).
IRLAB Therapeutics AB's annual market cap
increased
from Dec. 2023 (kr389.00 Mil) to Dec. 2024 (kr557.57 Mil) but then
declined
from Dec. 2024 (kr557.57 Mil) to Dec. 2025 (kr167.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. IRLAB Therapeutics AB's Enterprise Value for Today is kr82.19 Mil.
IRLAB Therapeutics AB (OSTO:IRLAB A) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IRLAB A vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Market Cap distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
IRLAB Therapeutics AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Market Cap of kr105.89 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #1191 out of 1431 companies in the Biotechnology industry, placing it in the top 83.2%.
Is IRLAB Therapeutics AB's Market Cap too high?
IRLAB Therapeutics AB's current Market Cap is kr105.89 Mil. Based on the distribution chart, IRLAB Therapeutics AB ranks #1191 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #1191 out of 1431 companies for Market Cap. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current Market Cap is kr105.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.78, compared to a current price of kr1.22 — trading 89.6% below its estimated fair value. The current Market Cap is kr105.89 Mil. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Market Cap is kr105.89 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.22 is trading 89.6% below its estimated GF Value™ of kr11.78.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
Market Cap: kr105.89 Mil
GF Value™: kr11.78 vs. price of kr1.22 (89.6% below fair value)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score
Get the complete analysis for OSTO:IRLAB A
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
